Earnings ·
KORU Medical reports Q3 net income of $0.2M on $11.6M revenue, raises full-year guidance to $48.5M
KRMDKORU Medical Systems, Inc.
KORU Medical Systems reported third-quarter 2026 net revenues of $11.6 million, an 11% increase year-over-year, driven by a 31.6% rise in domestic core sales. The company posted its second consecutive quarter of positive results with net income of $0.2 million and adjusted EBITDA of $1.3 million. Gross margin expanded to 65.2%, up from 60.2% in the prior year period, supported by lower manufacturing costs and tariff rebates. Management revised full-year 2026 revenue guidance upward to a range of $48.0–$48.5 million, reflecting expected growth of 17–18%. The company also raised its year-end cash balance expectation to over $8.0 million and signed new distribution agreements in Europe and Africa. KORU Medical Systems develops, manufactures, and commercializes large volume subcutaneous infusion solutions for home and ambulatory care.